Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) EBT Margin (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed EBT Margin for 13 consecutive years, with 6237.29% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 21635.0% to 6237.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8486.84% through Dec 2025, down 137465.0% year-over-year, with the annual reading at 10578.4% for FY2025, 781918.0% down from the prior year.
  • EBT Margin hit 6237.29% in Q4 2025 for Vistagen Therapeutics, up from 7525.97% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 90900.0% in Q1 2025 to a low of 42789.74% in Q1 2022.
  • Historically, EBT Margin has averaged 2076.2% across 5 years, with a median of 5613.88% in 2024.
  • Biggest five-year swings in EBT Margin: plummeted -4138454bps in 2022 and later surged 9670488bps in 2025.
  • Year by year, EBT Margin stood at 2942.46% in 2021, then plummeted by -84bps to 5422.89% in 2022, then surged by 72bps to 1545.01% in 2023, then crashed by -290bps to 6020.94% in 2024, then fell by -4bps to 6237.29% in 2025.
  • Business Quant data shows EBT Margin for VTGN at 6237.29% in Q4 2025, 7525.97% in Q3 2025, and 6186.48% in Q2 2025.